ERCC1 and cancer: Several studies have investigated the influence of ERCC1 in resistance to platinum compound in gastric cancer patients, and the majority of which revealed that patients with low levels of ERCC1 protein or mRNA expression were associated with favorable clinical outcomes of platinum based anti-cancer chemotherapy (32,39,40).